The characterization of the new lineage of IL-17-producing CD4 + T helper (Th17) cells has revolutionized our current understanding of T cell-mediated immunity. Over the past five years, there have been many twists and turns as the pathways that lead to Th17 cell differentiation have been elucidated. Not least of these was the discovery that TGF-b is a crucial cytokine for Th17 cell development, suggesting that Th17 and regulatory T cell subsets share reciprocal developmental pathways during the pathogenesis or control of inflammation. This review aims to bring together the observations that have formed current opinion on factors that promote and contain Th17 cell development, in both mouse and man. Unresolved controversies in this field are also discussed: For example, IL-23 is absolutely required for disease pathogenesis in many models of Th17-cellmediated autoimmunity, yet its role in Th17 cell development is relatively unclear.
Discovery of the Th17 Cell Subset-A Brief History
The recent advances in our understanding of the development of Interleukin (IL)-17-producing CD4 + effector T cells (Th17 cells) have led to a substantial revision of the T helper subset hypothesis. In 1986, a cornerstone of modern T cell biology was laid down by Mossman and Coffman when they published two landmark papers that proposed the Th1-Th2 hypothesis (Coffman and Carty, 1986; Mosmann et al., 1986) . The theory was based on the observation that distinct subsets of CD4 + T helper (Th) cells expressed discrete cytokine profiles that defined their function: Th1 cells induce cell-mediated inflammatory responses, and Th2 cells provide B cell help. Importantly, Coffman predicated that the effector cytokines produced by one subset of cells would regulate the development and function of the other. This concept has been validated over the past decades by molecular and genetic studies demonstrating a complex network of crossregulating Janus kinase (JAK) and signal transducer and activator of T cells (STAT) signaling pathways as well as transcriptional regulators such as T-bet and GATA-3 that coordinate genetic programming of the differentiating T cells. The Th1-Th2 hypothesis has served the immunology community well, particularly in understanding infectious and allergic diseases. Nevertheless, this model does not fit all systems; there are many inconsistencies when it comes to the study of organspecific autoimmune diseases. Th1-cell-mediated responses can certainly play an important role in the initiation of autoantigen-specific inflammation, exemplified by T cell passive-transfer studies. However, depletion of critical Th1-specific factors often gave contradictory results. For example, interferon (IFN)-g, the hallmark Th1 mediator that is critical for antitumor and antimicrobial responses, has paradoxical roles during chronic inflammation. Injection of IL-12 or IFN-g blocked experimental autoimmune encephalomyelitis (EAE) (Gran et al., 2004; Voorthuis et al., 1990) , whereas genetic or antibody-mediated depletion of IFN-g enhanced disease (Billiau et al., 1988; Willenborg et al., 1999) , suggesting that Th1-cell-produced factors might in fact regulate chronic inflammation. Deletion of the Th1 pathway molecules IL-12(p35), IL-12Rb2, IFN-gR, and STAT1 has further supported the role of Th1 cells in regulating rather than promoting many models of autoimmunity (Bettelli et al., 2004; Gran et al., 2002; Zhang et al., 2003) . Despite these observations, immunologists (including ourselves) continued to maintain that autoimmune diseases are predominantly driven by autoreactive Th1 cells.
In 2000, IL-23 was described as the pairing of the p19 subunit with the p40 subunit, also shared with IL-12 (Oppmann et al., 2000) ; thus began the study of the relative contribution of IL-12 and IL-23 to chronic inflammatory diseases. On the basis of the observation that IL-12 receptor b2 is expressed in naive T cells, whereas IL-23 receptor is only found in memory-activated T cells (Parham et al., 2002) , it seemed likely that because IL-12 is an important factor for Th1 cell development, subsequent exposure to IL-23 might be required for maturation of effector cells. This led to the hypothesis that these two related cytokines would initiate and then sustain Th1-cell-mediated immune responses, which were consistent with the observation that both the IL-12p40-and IL-23p19-deficient mice were resistant to Th1-associated autoimmune diseases . However, thorough analysis of the CNS-infiltrating cells in EAEresistant Il23a À/À mice showed the presence of neuroantigenspecific IFN-g secreting Th1 cells (albeit in low numbers) (Langrish et al., 2005) . In addition, Il12a À/À mice, which lack IL-12 but express functional IL-23, have few IFN-g secreting cells-yet these mice suffer from a hyperacute form of EAE Gran et al., 2002) . These unexpected findings suggested that IL-23 may regulate the function of a hitherto unknown population of inflammatory cells and prompted the search for an IL-23-dependent cell population capable of inducing chronic inflammation. In 2003, Gurney and colleagues showed that IL-23 promotes the production of IL-17 by activated T cells (Aggarwal et al., 2003) . Around the same time, Langrish, Murphy, and colleagues established that IL-23 is a key cytokine that induced expansion of IL-17-producing CD4 + T cells and that autoimmune resistant
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À/À mice have very few cells capable of secreting IL-17 (Langrish et al., 2005; Murphy et al., 2003) . IL-17 was known as a proinflammatory cytokine that mediates multiple chronic inflammatory responses including angiogenesis, recruitment of inflammatory cells, and induction of proinflammatory mediators by endothelial and epithelial tissues (reviewed in this issue of
Immunity by Ouyang et al. [2008] ). These observations led to the proposal that IL-23 is required for the development and/or expansion of inflammatory IL-17-producing cells (Langrish et al., 2005; Murphy et al., 2003) . On the basis of the characteristic cytokine profile, these cells were subsequently called ThIL-17 or Th17 (Langrish et al., 2005; McKenzie et al., 2006; Weaver et al., 2006) . Gene-expression analysis of the IL-17-producing cells showed a distinct gene-expression profile compared to Th1 cells (Langrish et al., 2005) . IL-23-driven cells expressed high amounts of IL-17A, IL-17F, and Tumor necrosis factor (TNF)a. In contrast, IL-12 specifically promoted expression of IFN-g, granzyme F, granzyme G, TNF-related apoptosis-inducing ligand (TRAIL), B lymphocyte stimulator (BLYS), and Fas ligand. These differences predicted that Th1 and Th17 cells probably have distinct immune functions. The concept that Th17 cells are responsible for driving autoimmune inflammation was finally established when it was shown that EAE was induced by passive transfer of IL-17-producing memory activated CD4 + T cells (Langrish et al., 2005) . In addition, both IL-12 and IFN-g were found to suppress IL-17 production (Langrish et al., 2005; Murphy et al., 2003) , and the lack of this suppression in IL-12-or IFN-g-deficient mice may contribute to EAE exaceration. Two additional landmark studies further showed that both Th1-and Th2-cell-specific transcriptional regulators (STAT1 and T-bet, STAT6 and GATA3, respectively) inhibited Th17 cell differentiation (Harrington et al., 2005; Park et al., 2005) . Thus, as predicted by Mossman and Coffman, effector cytokines produced by distinct T cell subsets governed the development and function of another. Collectively, these initial studies ushered in the concept of the Th17 hypothesis and began to change the way we viewed T cell biology and inflammatory diseases.
RORgt Is the Th17-Cell-Specific Transcription Factor After the observation that Th17 cells expressed a distinct subset of cytokines and chemokines compared to Th1 and Th2 cells, we performed an Affymetrix gene-expression analysis and found a number of Th17-cell-specific factors with potential DNA binding activities. In collaboration with Dan Littman's group, we confirmed that Rorc-which encodes RORgt, a retinoid orphan nuclear receptor-is specifically expressed in both human and mouse Th17 cells (Ivanov et al., 2006; Wilson et al., 2007) . The Th17 cells for this analysis were initially derived by stimulation of activated T cells with IL-23. Subsequent experiments showed that stimulation of naive T cells with transforming growth factor (TGF)-b and IL-6 (see below) also enhanced RORgt mRNA expression. Expression of RORgt in naive T cells was both necessary and sufficient to induce IL-17A, IL-17F, and IL-23R expression (Ivanov et al., 2006) . Furthermore, Rorc À/À mice are unresponsive to IL-23 stimulation, have reduced number of Th17 cells, and are resistant to autoimmune diseases. More recently, Dong and colleagues further demonstrated that RORa synergizes with RORgt to promote differentiation and function of Th17 cells (Yang et al., 2008 Cytokines that Regulate Th17 Cell Differentiation in Mice One major issue with the Th17 hypothesis in the early days was the lack of clarity for the initial regulation of Th17 cell lineage commitment. IL-23 was initially shown to induce IL-17 production in activated T cells, and because IL-23R is not expressed on naive T cells, it is not surprising that it was difficult to demonstrate direct induction of de novo Th17 cells by IL-23. However, two papers from Dong and colleagues and Weaver and colleagues suggested that this was possible if IFN-g and IL-4 were blocked (Harrington et al., 2005; Park et al., 2005) .
In early 2006, three research groups demonstrated that TGF-b acting in the presence of proinflammatory cytokines, particularly IL-6, is sufficient to induce naive T cell differentiation into Th17 cells (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006a ) ( Figure 1A ). Importantly, stimulation of naive T cells with TGF-b and IL-6 also enhanced RORgt mRNA expression (Ivanov et al., 2006) . These studies led to the general acceptance that IL-23 does not directly enhance the effects of TGF-b and may not be required during the initial differentiation of Th17 cells in the presence of TGB-b and IL-6. The role of IL-23 will be discussed later.
Previously, TGF-b had been associated primarily with antiinflammatory effects, particularly because it is intricately involved in the induction, maintenance, and function of Foxp3 + Treg cells that are generated in the thymus (natural nTreg cells) and induced in the periphery (inducible iTregs cells) (reviewed in this issue by Li and Flavell [2008] ). It was already known that IL-6 inhibited the suppressive function of nTreg cells (Pasare and Medzhitov, 2003) . The surprise was that the presence of IL-6 along with TGF-b, provided either exogenously or by nTreg cells present in the culture, resulted in upregulation of IL-17 in naive T cells (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006a) . In this context, IL-6 most probably serves two functions. First, IL-6 favors Th17 cell induction while inhibiting Treg cells: Korn et al. showed that IL-6-deficient mice are resistant to EAE in part because of their propensity to expand Treg cells rather than Th17 cells after immunization (Korn et al., 2007) . Second, IL-6 upregulates factors in naive T cells that are probably important for further development of the Th17 cell phenotype: IL-23R and IL-21 (Ivanov et al., 2006; Zhou et al., 2007) .
The in vivo source of TGF-b during Th17 cell differentiation is not clear. Several lines of evidence suggest that Foxp3 + Treg cells may be involved in the differentiation of Th17 cells through the provision of TGF-b. In vitro, dendritic cells (DCs) stimulated with certain microbial components such as curdlan and lipopolysaccharide (LPS) are capable to induce Th17 cells, but this requires an exogenous source of TGF-b, which can be provided by the presence of Treg cells in the culture (LeibundGut-Landmann et al., 2007; Veldhoen et al., 2006a) . In contrast, zymosan and Mycobacterium tuberculosis appear to induce sufficient TGF-b from DC to negate this requirement for Treg cells in vitro (Veldhoen et al., 2006b ). However, Th17 cells are notably absent in mice that lack TGF-b production only in CD4 + T cells , even after immunization with adjuvant containing Mycobacterium, further suggesting that T cell sources of TGF-b are required for induction of the Th17 cell response in vivo. It was nevertheless not clarified whether Treg cells are the important contributor of TGF-b. In contrast to IL-6, IL-2 is required for iTreg cell generation and nTreg cell survival Setoguchi et al., 2005; Zheng et al., 2007a) but is dispensible for, and in fact inhibits, Th17 cell differentiation . Hence, IL-2-deficient mice have large numbers of Th17 cells but are deficient in peripheral Treg cells, and they suffer severe lymphoproliferative immunopathology. This is perhaps surprising, given the dependence of other helper T cell subsets on IL-2, and suggests that additional factor(s) substitute for IL-2 during Th17 cell development. One candidate is IL-21, another member of the common gamma chain cytokine family along with IL-2. IL-21 is produced by Th17 cells upon stimulation by IL-6 and by IL-21 itself, although other subsets of T cells may also produce IL-21; it is also thought to promote B cell responses (IL-21 functions are reviewed by Ouyang et al. [2008] ). IL-21 acts in an autocrine manner to promote Th17 cell differentiation along with TGF-b, and may even be able to compensate for absent IL-6 for induction of RORgt and Th17 cell differentiation (Korn et al., 2007; Nurieva et al., 2007; Zhou et al., 2007) . Although it is clear that IL-21 enhances the rate of Th17 cell conversion, it may not be essential for the lineage commitment of Th17 cells or their pathogenic functions.
Much like IL-2, retinoic acid has recently been shown to promote Foxp3 + Treg cell induction over Th17 cell induction by TGF-b, even in the presence of IL-6. Retinoic acid binds retinoic acid receptor (RAR) to directly induce Foxp3 expression and inhibits RORgt expression and IL-17 production (Elias et al., 2008; Mucida et al., 2007; Schambach et al., 2007) (Figure 1A ). In the intestine and draining mesenteric LN, CD103 + dendritic cells have been shown to metabolize dietary beta carotene (vitamin A) to secrete retinoic acid (Coombes et al., 2007) . These CD103 + DCs also produce TGF-b and are strong inducers of Foxp3 + regulatory T cells but poor inducers of Th17 cells unless retinoic acid is inhibited. In contrast, CD103
À DCs produce IL-6, TNFa, and IL-23 but low amounts of TGF-b, and they are poor Treg cell inducers. Thus, in the context of TGF-b, retinoic acid and IL-6 may be key switch factors that promote the balance between Treg cell and Th17 cell development in the gut mucosa. The finding that retinoic acid is produced by DCs in this site may explain why the Th17 cell population is limited despite relatively high amounts of IL-6 in the intestinal tract. Treg cells are clearly important in maintaining tolerance in the intestine, but the role of Th17 cells in this site is less clear. Th17 cells have been isolated from the gut mucosa of patients with active Crohn's disease and are found in some mouse models of colitis (Annunziato et al., 2007; Kullberg et al., 2006; Yen et al., 2006) . On the other hand, depletion of IL-17 exacerbated inflammation in the DSS model of colitis in mice (Ogawa et al., 2004) , suggesting that IL-17 may have a protective and/or reparative role in the intestine after exposure to toxins or pathogens. The cellular source of this ''protective'' IL-17 has yet to be determined because many cell types, including myeloid cells (Kullberg et al., 2006) , can produce IL-17. Much as the Th1 and Th2 cell subsets crossregulate the differentiation of the other, they also appear to negatively regulate differentiation of Th17 cells. Addition of IL-12, IFN-g, or IL-4 to cultures inhibits either IL-23-or TGF-b plus IL-6-stimulated differentiation of mouse and human Th17 cells (Annunziato et al., 2007; Harrington et al., 2005; Murphy et al., 2003; Park et al., 2005; Wilson et al., 2007) . It is not clear for how long developing Th17 cells are susceptible to this regulation. One paradox in this regard is the observations from many investigators that a subset of Th17 cells may coproduce IFN-g. This is particularly apparent when looking at T cells from sites of inflammation, for example, the brain of mice after EAE induction (Chen et al., 2006; McGeachy et al., 2007) or the intestine of patients with active Crohn's disease (Annunziato et al., 2007) . This suggests that IFN-g cannot always downregulate IL-17 production and may in fact contribute to the pathogenic function of Th17 cells, although this has not been thoroughly investigated. In relation to this point, it is interesting to note that mice lacking the Th1 transcription factor T-bet produce greater numbers of IL-17 + cells (Park et al., 2005) , presumably because of reduced IFN-g production, yet these mice are also extremely resistant to Th17-cell-mediated models of inflammation, including EAE (Bettelli et al., 2004) . It is still not clear whether the important contribution of T-bet in these models is toward the function of Th17 cells, Th1 cells, or to other cells such as DCs. T-bet may be expressed in Th17 cells stimulated with IL-23 (Chen et al., 2006) , and T-bet has been suggested to positively regulate IL-23R expression (Gocke et al., 2007) . However, because IL-6 also stimulates IL-23R upregulation in the presence of TGF-b, which represses T-bet, it does not seem likely that this fully explains the requirement for T-bet in Th17 cells. Stimuli that Promote Th17-Cell-Inducing Dendritic Cells As the cytokines that promote Th17 cell differentiation have been delineated, so have the microbial factors and pathways that stimulate the Th17-cell-inducing phenotype in DC. IL-17 is important in the control or clearance of various pathogens (reviewed by Ouyang et al. [2008] and Umemura et al. [2007] ). These include the extracellular bacteria Klebsiella pneumonia (Ye et al., 2001) , Citrobacter rodentium , and Borrelia Burgdorferi (Infante-Duarte et al., 2000) , as well as systemic infection with the fungal pathogen Candida albicans (Huang et al., 2004) . Candida-specific Th17 cell responses have also been observed in peripheral blood of human donors (Acosta-Rodriguez et al., 2007b) . Th17 cells do not appear to be required for clearance of Mycobacterium infection but may facilitate recruitment of Th1 cells to the lungs and thus aid the response (Khader et al., 2007 ). An important point to bear in mind when considering effects of absence of IL-17 signaling is that IL-17 can also be produced as part of the innate immune response. Several adjuvants including LPS and CpG promote some Th17-cell-promoting cytokines such as IL-23 and IL-6 production from DCs, but these components also induce strong IL-12 responses and therefore promote Th1 cell responses as well as low amounts of IL-17 (LeibundGut-Landmann et al., 2007) . However, the Saccharomyces cerevisiae cell-wall component zymosan, as well as Mycobacteria, which both contain ligands for TLR2 but do not signal exclusively through this pathway, promote strong Th17 cell responses in murine cell culture and in vivo (Veldhoen et al., 2006b) . Mycobacterium tuberculosis is the key ingredient of complete Freund's adjuvant (CFA), the widely used adjuvant for murine immunizations; although CFA was long thought to induce Th1 cell responses, it is now clear that it also very effectively induces Th17 cell responses. This is associated with the capacity to strongly induce IL-6 and IL-23 as well as TGF-b, allowing the differentiation of naive T cells into Th17 cells without the requirement for addition of exogenous TGF-b as was required for LPS-induced Th17 cells (Veldhoen et al., 2006a) . The source of antigen presenting cell (APC) may also influence the response elicited: Acosta-Rodriguez and colleagues found that monocytes from human PBMC produced large amounts of IL-1 and IL-6 but not IL-12 in response to various TLR stimulants including LPS and peptidoglycan and were therefore good inducers of Th17 cells. However, generation of dendritic cells by culture of monocytes with IL-4 resulted in cells that produced greater amounts of IL-12 in response to these stimulants and were therefore poor inducers of the Th17 cell phenotype (Acosta-Rodriguez et al., 2007a) .
b-glucan components in zymosan also signal through TLRindependent pathways to promote Th17 cell induction (Gantner et al., 2003) . Fungal b-glucans, including Curdlan, bind to the C type lectin Dectin-1 on dendritic cells and trigger IL-23 production (LeibundGut-Landmann et al., 2007) . These Dectin-1-activated DCs also produce proinflammatory cytokines including TNFa and IL-6 and upregulate costimulatory molecules such as CD80 and CD40. However, in contrast to TLR-stimulated DCs, Dectin-1 stimulated DCs do not produce substantial amounts of IL-12 and appear to preferentially induce Th17 over Th1 cell responses. An additional TLR-independent pathway for generation of Th17-promoting DC is the ligation of the intracellular receptor NOD2 by muramyldipeptide (MDP)-a breakdown product of internalized peptidoglycan (van Beelen et al., 2007) . The signaling pathways for NOD2 and Dectin-1 may converge in their shared use of caspase recruitment domain (CARD) 9.
Interestingly, peptidoglycan joins zymosan as one of the few microbial components that can be substituted for Mycobacteria during the induction of autoimmune inflammation in the mouse model of EAE (Visser et al., 2005) . It is likely that the common factor is the triggering of Th17-cell-promoting pathways in DCs by these pathogen components, although this has not been investigated for peptidoglycan. In humans, the link between infection and autoimmune disease remains intriguing yet elusive. However, the discovery of pathogens that preferentially promote Th17 cell responses and their corresponding ability to promote Th17-cell-mediated autoimmune inflammation in murine models is very suggestive. Further compelling examples of this link are found in murine arthritis models. Infection with Borrelia burgdorferi, the causative agent of Lyme's disease, can lead to subsequent development of arthritis, and in mice, this is dependent on IL-17 (Burchill et al., 2003) . Fungal b-glucans have also been found to trigger onset of arthritis via dectin-1 receptor activation in genetically susceptible SKG mice (bearing a mutation in the SH2 domain of ZAP70) (Yoshitomi et al., 2005) .
Th17 Cells in Immunopathology
It is now clear that IL-23 and IL-17 are associated with a number of human autoimmune disorders, validating the findings in mouse models (IL-17 functions are more extensively reviewed by Ouyang et al. [2008] ). One of the earliest human disease associations for IL-17 was demonstrated in rheumatoid arthritis (RA). Lebecque and coworkers showed that IL-17 induced human synovial cells to produce IL-6, IL-8, and TNF, suggesting that IL-17 may directly act on stromal cells to promote inflammation (Fossiez et al., 1996; Kotake et al., 1999) . In addition, Th17 cells found in human arthritic synovium expressed receptor activator of nuclear factor kappa B ligand (RANKL), which is a potent cytokine that promotes formation of bone resorptive osteoclasts . These observations suggest that Th17 cells are likely to be highly pathogenic in RA. Likewise, IL-17 + CD4 + and CD8 + T cells have been identified in active lesions in the brain from multiple sclerosis (MS) patients (Tzartos et al., 2008) . Prat and colleagues elegantly demonstrated that receptors for IL-17 and IL-22 are present on inflamed endothelium in MS lesions and that these cytokines may potentiate migration of inflammatory T cells across the blood-brain barrier (Kebir et al., 2007) . Psoriasis is another immune-mediated inflammatory disease that has been linked to inappropriate Th17 cell responses. The Th17 factors RORgt, IL-17, IL-22, and IL-23 mRNA are all elevated in psoriatic lesional skin (Lee et al., 2004; Teunissen et al., 1998; Wilson et al., 2007; Wolk et al., 2004) . Anti-p40 treatment-which inhibits both IL-12 and IL-23-was highly efficacious for treatment of psoriasis (Krueger et al., 2007) . Future clinical studies using anti-p19 will determine whether IL-23 is the target of choice for treatment of this skin inflammatory disease. Currently, one of the most powerful tools for studying human diseases is genome-wide disease-association analysis. Using this strategy, Cho and colleagues screened 547 patients and case-control cohorts and identified IL-23R as an inflammatorybowel-disease gene (Duerr et al., 2006) . A number of IL-23R single-nucleotide polymorphisms (SNPs) including Arg381Gln were found to be highly associated with IBD. This study underscores the critical importance of IL-23 signaling in regulation of chronic tissue inflammation. At this point, it is not clear whether it is gain of function or loss of function that lead to human IBD. Additional genetic studies have since shown that IL-23R polymorphism is also linked to psoriasis, psoriatic arthritis, ankylosing spondylitis, and multiple-sclerosis-disease susceptibility (Burton et al., 2007; Capon et al., 2007; Cargill et al., 2007; Illes et al., 2008; Smith et al., 2007) . Together, these studies demonstrate that IL-23 and/or IL-23R are potential targets for treatment of chronic inflammatory disorders such as psoriasis and Crohn's disease. In addition, because IL-17 is clearly involved in joint inflammation and bone erosion, it is probably an effective therapeutic target for treatment of RA.
TGF-b-IL-6 Promotes IL-10: A Self-Regulating Mechanism for Th17 Cells? Regulation of robust adaptive T cell responses is crucial for preventing host tissue damage during clearance of infectious pathogens and most probably also during periods of remission from autoimmune disease. In this regard, IL-10 has long been known to be important for regulation of Th1 cell responses to pathogens. However, it was only recently shown that the Th1 effector cells are themselves important coproducers of IL-10 with IFN-g, and thus ''self-regulate'' (Anderson et al., 2007; Jankovic et al., 2007) . IL-27 production by activated DCs promotes IL-10 production in Th1 cells and may therefore be an important mediator of this type of regulation Fitzgerald et al., 2007; Stumhofer et al., 2007) .
Our lab and others have recently demonstrated that Th17 cells generated in the presence of TGF-b plus IL-6 include a subset of cells that produce IL-10 along with IL-17 (McGeachy et al., 2007; Stumhofer et al., 2007) . Unlike Th1 cells, IL-27 was found to inhibit the generation of Th17 cells but promote IL-10 (Stumhofer et al., 2007) . Hence, although IL-27 is known to regulate the severity of Th17 cell responses, the mechanisms may be different to Th1 cell regulation.
While investigating the regulation of effector Th17 cells, we found that restimulation of activated Th17 cells in the presence of TGF-b and IL-6 also resulted in IL-10 production concomitant with increased IL-17 (McGeachy et al., 2007) . Analogous to the Th1 cell situation, this T cell-produced IL-10 was able to regulate Th17 cell immunopathology, which was demonstrated by reduced disease severity after cotransfer of TGF-b-plus-IL-6-stimulated T cells with IL-23-stimulated (pathogenic) T cells. Hence, we proposed that continued exposure of differentiating Th17 cells to TGF-b and IL-6 results in regulation through production of IL-10, as well as other mechanisms (Figure 2 ). Just as Th1 cells that produce IL-10 are not considered regulatory T cells, we do not consider these cells ''regulatory Th17 cells'' but rather that this IL-10 production may be a mechanism of self-regulation of the otherwise potentially dangerous Th17 cell response. Importantly, IL-23 does not maintain the IL-10 induced by TGFb plus IL-6 but also does not directly inhibit IL-10 production. Hence, stimulation with IL-23 results in gain of pathogenic function, whereas continued exposure to TGF-b may self-limit the response even in the presence of IL-23, and the balance of signals will determine the outcome of the response.
There is an unresolved question over whether Treg cells can suppress Th17 cells, but there are suggestions that in contrast to IFN-g, IL-17 production and/or Th17 cell development may not be downregulated by Treg cells in vitro (Annunziato et al., 2007; O'Connor et al., 2007) . Defective Treg cell function or numbers has been associated with several autoimmune diseases that are now also Th17-cell-associated (Baecher-Allan and Hafler, 2004) . Also, there is some debate over whether DCs or T cells are more pivotal targets for Treg cells. Our studies with TGF-b and IL-6 activation of effector cells suggested that although IL-17 may not be downregulated, the outcome of interactions between Treg cells and effector Th17 cells could in fact be regulation of the inflammatory response. However, the issue of whether Treg cells can effectively inhibit Th17 cell responses has yet to be fully clarified. In any case, it appears that continued strong proinflammatory signals in the presence of TGF-b plus IL-6 will trigger mechanisms of self-regulation in Th17 cells to limit bystander immunopathology.
What Is the Role of IL-23 in Th17 Cell Biology?
The findings that TGF-b plus IL-6 alone may not be sufficient to induce the full pathogenic Th17 cell phenotype coupled with the observations in IL-23-deficient mice raise again the question: What is the bona fide function of IL-23 in Th17 cell biology? Because IL-23 is not required for initial IL-17 induction in vitro, and the IL-23R is not expressed on naive T cells, the early proposals that IL-23 directly drives differentiation of the Th17 cell lineage (Harrington et al., 2005; Langrish et al., 2005; Park et al., 2005) have been predominantly discounted. Several alternative suggestions for the function of IL-23 have been put forth, and even started to gain acceptance, but we feel the evidence is still inconclusive.
The most commonly presumed function of IL-23 is to expand differentiated Th17 cells or maintain IL-17 production, two overlapping ideas based on similar data. These conclusions were reached after in vitro observations that the presence of IL-23 during culture of activated cells results in increased proliferation of activated T cells (Oppmann et al., 2000) and increased frequencies of IL-17 + cells (Langrish et al., 2005) or that IL-23 was required during restimulation of TGF-b plus IL-6-stimulated cells to maintain their IL-17 production (Veldhoen et al., 2006a) . In a similar vein, it has also been suggested that IL-23 may stabilize the phenotype of Th17 cells through STAT3-dependent mechanisms Zhou et al., 2007) , although IL-6 and IL-21 also share the STAT3 signaling pathway with IL-23. Finally, an alternative hypothesis for the current data is that IL-23 is a survival factor for Th17 cells (Elson et al., 2007) .
Although all of these suggestions broadly concur with the reduced frequencies of IL-17 + cells generated in IL-23-deficient mice, they have yet to be convincingly supported in vivo, and these functions of IL-23 may not provide a full picture. In addition, they do not incorporate the findings that IL-23 can promote expression of additional pathogenic factors in Th17 cells, including IL-22, that are required for disease pathogenesis in certain models including psoriasis (Liang et al., 2006; Zheng et al., 2007b ).
In the Citrobacter rodentium model described by Mangan et al., + cells were observed in Il23a À/À mice but were unable to clear the infection . The mechanisms for this observation were not investigated, but one explanation could be a requirement for IL-23 to promote the effector function of Th17 cells. However, it is also clear that IL-23 can promote inflammatory functions in cells of the innate immune system Uhlig et al., 2006) (Michel et al., 2007) ; therefore, the results obtained in IL-23-deficient animals need to be interpreted with care. Rather than expanding or stabilizing pre-existing Th17 cells, could IL-23 in fact have an earlier role during their differentiation in vivo? IL-23R expression is upregulated remarkably early in response to IL-6 (within 1 to 2 days [Zhou et al., 2007] , making it possible that IL-23 begins to act quite early during Th17 cell differentiation. These findings suggest that IL-23 may be more central to differentiation of effector Th17 cells than is currently appreciated, and it might not merely expand or enhance survival of pathogenic Th17 cells.
Summary and Future Perspectives
Over the past few years, there have been remarkable advances in our understanding of the regulation of T cell responses during immune homeostasis and disease pathogenesis. The key areas of discovery have been identification of the cytokines and transcriptional regulators that control the function of distinct T cell subsets. We now recognize that specific cytokines can induce activation of transcriptional factors such as T-bet, GATA3, RORgt, and Foxp3, which control the development and function of Th1, Th2, Th17, and Treg cells, respectively. However, there are still many unknowns. Although in vitro studies suggest that T cells follow a strict developmental program when activated with discrete cytokines, in vivo T cells are actually exposed to a complex cytokine milieu and display considerable plasticity. For example, many of the CD4 + T cells isolated from an inflamed central nervous system during EAE do not exclusively belong to either the Th1 or Th17 cell subsets as currently defined because they coproduce IL-17 and IFN-g. For many years, the presence of Th1 cell signature cytokines implicated Th1 cells in many of the diseases that are now associated with Th17 cells, raising the possibility that inflammatory autoimmune diseases are not necessarily restricted to just Th1 or Th17 cell type responses. The possible synergistic or antagonistic interactions between these subsets in vivo need to be more fully clarified.
The study of human Th17 cell differentiation and function is only in its infancy, and there remains much to know about how the cells that drive inflammation in human diseases are generated. Although human genetic evidence suggests that targeting IL-23 or IL-23R may benefit IBD patents, more work is also needed to understand the precise function of this potent immune regulator. 
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